Mumbai, India : Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter and financial year ended March 31, 2025.

Financial Summary (All numbers in INR Mn.)

QUARTERLY CONSOLIDATED FINANCIALS	Q4FY25	Q3FY25	Growth (QoQ)	Q4FY24	Growth (YoY)
Revenue from Operations	11,974	11,377	5%	11,758	2%
EBITDA	2,524	2,303	10%	2,557	(1%)
EBITDA %	21%	20%		22%
PAT	1,520	1,176	29%	1,296	17%
PAT %	13%	10%		11%

ANNUAL CONSOLIDATED FINANCIALS	FY25	FY24	Growth (YoY)
Revenue from Operations	44,816	45,064	(1%)
EBITDA	9,452	8,560	10%
EBITDA %	21%	19%
PAT	5,015	4,053	24%
Net Profit Margin	11%	9%

Financial and Business Summary for Q4FY25

• Revenue from Operations of Q4FY25 stood at INR 11,974 mn, a growth of 2% YoY, Sustained increase in formulations’ share despite slowdown in productivity of Gagillapur facility with ongoing US FDA remediation activities. Revenue share from the North America increased to 79% in Q4 FY25 as compared to 70% in Q4 FY24.
• Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Finished dosages contribute 12%, 10%, and 77% of revenue from operations respectively for Q4FY25.
• ROCE is at 16.6% as compared to 16.5% YoY.
• Net debt stood at INR 7,061 mn, a reduction of INR 1,360 mn and Net debt to EBITDA at

0.75x

Commenting on the results, Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “We are pleased to report a resilient bottom line and cash flow performance this year, despite sales remaining steady. This was achieved with a profitable Formulations growth of 18%, even though we proactively paused Gagillapur’s production operations in Sep-24 for more than a month to re-assess the risks and undertake necessary USFDA remediation activities. Productivity of Gagillapur facility has been lower in H2 FY25 with ongoing remediation activities. Our strong financial performance reflects the success of our strategic initiatives, particularly our focus on enhancing our product mix by prioritizing high- margin offerings and expanding our portfolio of non-legacy molecules. This reflects the strength and adaptability of our business model, and our unwavering commitment”.